Previous Close | 10.500 |
Open | 10.520 |
Bid | 10.100 x N/A |
Ask | 10.180 x N/A |
Day's Range | 10.180 - 10.700 |
52 Week Range | 10.040 - 14.020 |
Volume | |
Avg. Volume | 84,190 |
Market Cap | 6.171B |
Beta (5Y Monthly) | -0.38 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 0.02 (0.20%) |
Ex-Dividend Date | Jul 04, 2024 |
1y Target Est | N/A |
Yunkang Group Limited ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its score in the "S&P Global Corporate Sustainability Assessment" ("S&P Global CSA").
Yunkang Group Limited ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its annual results for the year ended December 31, 2023 (the "Reporting Period"). In 2023, the Group continued to expand its business network and services across the country, the Group's revenue reached RMB891.5 million. The Group's routine testing business achieved a healthy and steady year-on-year growth of 26.9% during the Reporting Period. Due to enhanced